Latest News
Dec 22, 2025
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed JournalResults Underscore PRP Candidacy as a Disruptor of the Tumor Microenvironment MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a…
View All Press Releases